Drugmakers increase pressure on Russian state during public procurements

Russia is faced with a significant delay of drug supplies to the domestic market, as producers delay signing of contracts with the local state in an attempt to make a deal with higher prices for them, according to a recent report published by the Institute of State and Municipal Administration of the Higher School of Economics (ISMU), one of Russia’s leading research institutions in the field of finance, reports The Pharma Letter’s local correspondent.

Due to this, state customers have to conduct tenders three to five times, which negatively affects competition and leads to consolidation of the market by a few large players.

Currently many of suppliers continue ignoring or disrupting state tenders for drug procurements, seeking higher prices for their products.